HER2/HER3-targeting BsADC

N/A

Report date: 2025/08/04 17:43:36

Base Information

Drug NameHER2/HER3-targeting BsADC
Drug Alias NameHER2/HER3-targeting bispecific ADC
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-HER2Anti-Receptor tyrosine-protein kinase erbB-3
TargetsReceptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Jiaotong UniversityJecho Laboratories IncJecho Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJecho Laboratories Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A